being studied.

Where the line terminates in Downtown Seattle remains a question. The Route 120 current ends just north of Virginia Street on Third Avenue while three RapidRide Lines operate on same street. The RapidRide C Line happens to have the most similar characteristics since it runs from West Seattle through Downtown and then terminates in South Lake Union. The other RapidRide Lines–D and E–originate north of Downtown and converge on Third Avenue near Bell Street. The lines then continue south toward the Chinatown-International District. None of the RapidRide Lines terminate in the central core. Obviously, creating some consistency in service patterns between RapidRide Lines seems sensible to do and extending the H Line could help deliver more local service in Belltown and beyond depending upon where the linethe consortium.

Charles completed his MDPhD in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician/scientist medical oncology training in 2008. Charles combines his laboratory research at the Francis Crick Institute with clinical duties focussed on biological mechanisms of cancer drug resistance. Charles was made Fellow of the Royal College of Physicians in April 2011 and Chair in Personalised Cancer Medicine and Consultant Thoracic Medical Oncologist at UCL Hospitals in November 2011. Charles is the Chief Investigator of the CRUK TRACERx lung cancer evolution study and was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences in 2013, Fellow of the European Academy of Cancer Sciences in 2013, and Fellow of the Academy of Medical Sciences in 2015. Charles